Pasithea Therapeutics (KTTA) Consolidated Net Income (2021 - 2024)
Historic Consolidated Net Income for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to -$3.2 million.
- Pasithea Therapeutics' Consolidated Net Income fell 1870829.24% to -$3.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$13.9 million, marking a year-over-year decrease of 296329.1%. This contributed to the annual value of -$13.9 million for FY2024, which is 296329.1% down from last year.
- According to the latest figures from Q4 2024, Pasithea Therapeutics' Consolidated Net Income is -$3.2 million, which was down 1870829.24% from -$3.0 million recorded in Q3 2024.
- In the past 5 years, Pasithea Therapeutics' Consolidated Net Income registered a high of $630143.0 during Q4 2021, and its lowest value of -$3.9 million during Q2 2024.
- Moreover, its 4-year median value for Consolidated Net Income was -$549609.0 (2021), whereas its average is -$1.3 million.
- Its Consolidated Net Income has fluctuated over the past 5 years, first skyrocketed by 9841.25% in 2023, then tumbled by 1870829.24% in 2024.
- Over the past 4 years, Pasithea Therapeutics' Consolidated Net Income (Quarter) stood at $630143.0 in 2021, then tumbled by 268.9% to -$1.1 million in 2022, then surged by 98.41% to -$16895.0 in 2023, then plummeted by 18708.29% to -$3.2 million in 2024.
- Its Consolidated Net Income was -$3.2 million in Q4 2024, compared to -$3.0 million in Q3 2024 and -$3.9 million in Q2 2024.